Total Payments
$235,997
2024 Payments
$20,444
Companies
9
Transactions
251
Medicare Patients
2,542
Medicare Billing
$277,273
Payment Breakdown by Category
Other$173,510 (73.5%)
Consulting$27,537 (11.7%)
Travel$24,700 (10.5%)
Food & Beverage$8,485 (3.6%)
Research$1,747 (0.7%)
Education$18.34 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $173,510 | 70 | 73.5% |
| Consulting Fee | $27,537 | 9 | 11.7% |
| Travel and Lodging | $24,700 | 54 | 10.5% |
| Food and Beverage | $8,485 | 105 | 3.6% |
| Unspecified | $1,747 | 12 | 0.7% |
| Education | $18.34 | 1 | 0.0% |
Payments by Type
General
$234,250
239 transactions
Research
$1,747
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $160,981 | 157 | $0 (2024) |
| Genentech USA, Inc. | $70,135 | 66 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,980 | 1 | $0 (2022) |
| SANOFI US SERVICES INC. | $1,634 | 11 | $0 (2024) |
| United Therapeutics Corporation | $717.73 | 9 | $0 (2024) |
| Paragonix Technologies, Inc. | $282.35 | 4 | $0 (2024) |
| GlaxoSmithKline, LLC. | $230.00 | 1 | $0 (2018) |
| Gilead Sciences Inc | $21.02 | 1 | $0 (2017) |
| Philips Electronics North America Corporation | $15.50 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,444 | 37 | Boehringer Ingelheim Pharmaceuticals, Inc. ($18,371) |
| 2023 | $19,590 | 18 | Boehringer Ingelheim Pharmaceuticals, Inc. ($19,458) |
| 2022 | $17,944 | 19 | Boehringer Ingelheim Pharmaceuticals, Inc. ($15,537) |
| 2021 | $30,055 | 20 | Boehringer Ingelheim Pharmaceuticals, Inc. ($28,641) |
| 2020 | $17,571 | 12 | Boehringer Ingelheim Pharmaceuticals, Inc. ($17,571) |
| 2019 | $44,442 | 37 | Genentech USA, Inc. ($29,012) |
| 2018 | $34,108 | 51 | Boehringer Ingelheim Pharmaceuticals, Inc. ($22,567) |
| 2017 | $51,844 | 57 | Genentech USA, Inc. ($28,417) |
All Payment Transactions
251 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $1,137.15 | General |
| 12/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $105.81 | General |
| 11/18/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | Cash or cash equivalent | $174.43 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 11/18/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | Cash or cash equivalent | $126.88 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 11/18/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | Cash or cash equivalent | $6.58 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 11/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,240.00 | General |
| Category: RESPIRATORY | ||||||
| 11/01/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $19.61 | General |
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $341.39 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $299.93 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $272.70 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $84.40 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $74.87 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $27.23 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $27.23 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/25/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $198.74 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,240.00 | General |
| Category: RESPIRATORY | ||||||
| 10/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $53.60 | General |
| Category: RESPIRATORY | ||||||
| 10/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $40.09 | General |
| Category: RESPIRATORY | ||||||
| 10/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $311.18 | General |
| 10/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $130.38 | General |
| Category: RESPIRATORY | ||||||
| 10/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $138.97 | General |
| 10/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $107.02 | General |
| Category: RESPIRATORY | ||||||
| 10/01/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $115.75 | General |
| Category: RESPIRATORY | ||||||
| 09/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,680.00 | General |
| Category: RESPIRATORY | ||||||
| 09/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $79.93 | General |
| Category: RESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation | SANOFI US SERVICES INC. | $1,634 | 11 |
| A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | United Therapeutics Corporation | $112.63 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 644 | 1,021 | $323,812 | $67,722 |
| 2022 | 13 | 624 | 1,070 | $288,140 | $65,204 |
| 2021 | 13 | 603 | 1,063 | $296,974 | $66,912 |
| 2020 | 13 | 671 | 1,133 | $267,635 | $77,436 |
Total Patients
2,542
Total Services
4,287
Medicare Billing
$277,273
Procedure Codes
63
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 77 | 156 | $95,070 | $17,178 | 18.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 152 | $52,611 | $14,781 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 94 | 142 | $59,387 | $10,466 | 17.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 38 | $24,529 | $5,360 | 21.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 41 | $17,391 | $3,985 | 22.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 26 | 30 | $8,700 | $2,874 | 33.0% |
| 94375 | Test to measure rate of airflow | Facility | 2023 | 149 | 252 | $17,136 | $2,710 | 15.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $13,709 | $2,420 | 17.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $11,608 | $2,400 | 20.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 33 | $6,823 | $2,182 | 32.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 12 | $6,666 | $1,547 | 23.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 15 | 16 | $4,524 | $881.76 | 19.5% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 47 | 48 | $2,736 | $454.96 | 16.6% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 48 | 49 | $2,058 | $348.48 | 16.9% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 15 | 18 | $864.00 | $133.28 | 15.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 44 | 169 | $44,109 | $14,514 | 32.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 46 | 110 | $66,770 | $12,753 | 19.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 79 | 125 | $52,000 | $9,212 | 17.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 26 | 27 | $15,660 | $4,498 | 28.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 39 | 74 | $13,764 | $4,440 | 32.3% |
| 94003 | Follow-up inpatient or observation ventilation assistance and management | Facility | 2022 | 19 | 75 | $20,700 | $4,172 | 20.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 26 | 26 | $19,708 | $3,933 | 20.0% |
| 94375 | Test to measure rate of airflow | Facility | 2022 | 150 | 256 | $17,408 | $2,787 | 16.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 26 | $9,183 | $2,448 | 26.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $8,736 | $2,389 | 27.3% |
About Dr. Daniel Dilling, MD
Dr. Daniel Dilling, MD is a Pulmonary Disease healthcare provider based in Maywood, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1659358539.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Dilling, MD has received a total of $235,997 in payments from pharmaceutical and medical device companies, with $20,444 received in 2024. These payments were reported across 251 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($173,510).
As a Medicare-enrolled provider, Dilling has provided services to 2,542 Medicare beneficiaries, totaling 4,287 services with total Medicare billing of $277,273. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine
- Location Maywood, IL
- Active Since 12/30/2005
- Last Updated 06/24/2021
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1659358539
Products in Payments
- OFEV (Drug) $60,813
- Esbriet (Biological) $53,415
- GLASSIA (Biological) $1,980
- REZUROCK (Drug) $1,634
- GILOTRIF (Drug) $886.61
- TYVASO (Drug) $443.41
- ANORO (Drug) $230.00
- SherpaPak (Device) $122.31
- Steen Solution (Device) $113.95
- STIOLTO RESPIMAT (Drug) $26.34
- Xolair (Biological) $16.73
- (8874) inCourage (Device) $15.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Maywood
Marilyn Glassberg, Md, MD
Pulmonary Disease — Payments: $380,237
Pulmonary Disease $380,237
Dr. Matthew Nobari, Md, MD
Pulmonary Disease — Payments: $204,781
Pulmonary Disease $204,781
James Gagermeier, Md, MD
Pulmonary Disease — Payments: $15,923
Pulmonary Disease $15,923
Daniel Djondo, M.d, M.D
Pulmonary Disease — Payments: $4,240
Pulmonary Disease $4,240
Sana Quddus, M.d, M.D
Pulmonary Disease — Payments: $1,181
Pulmonary Disease $1,181
Ciaran Cunningham, Md, MD
Pulmonary Disease — Payments: $877.41
Pulmonary Disease $877.41